Doxorubicin eosomes - Eos Biosciences

Drug Profile

Doxorubicin eosomes - Eos Biosciences

Alternative Names: Doxorubicin eosomes; Eos-001

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eos Biosciences
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; ERBB-3 receptor modulators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Solid tumours

Most Recent Events

  • 17 Oct 2017 The U.S. Patent and Trademark Office issues U.S. Patent No. 9 789 201 for doxorubicin eosomes for Breast cancer
  • 20 Sep 2017 Eos 001 is covered by patent protection in USA and US PTO grants patent for Eos 001 for Solid tumours and Breast cancer
  • 13 Sep 2017 Preclinical trials in Breast cancer (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top